11 - 20 of 422 Results
Condition Status ˆ Requirements ˇ Location Near You ˇ
Human Immunodeficiency Virus (HIV)
Recruiting

No Limit

To find a center near you, please provide a Country or Postal Code.

212305-Juluca® drug use-results survey
212305-Juluca® drug use-results survey
Human Immunodeficiency Virus (HIV)
Available
18+

To find a center near you, please provide a Country or Postal Code.

207214-Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)
207214-Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)
Human Immunodeficiency Virus (HIV)
Recruiting
12-99

To find a center near you, please provide a Country or Postal Code.

114916-Dolutegravir Expanded Access Study
114916-Dolutegravir Expanded Access Study
Human Immunodeficiency Virus (HIV)
Recruiting
12+

To find a center near you, please provide a Country or Postal Code.

204731-An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of TRIUMEQ administered in Korean subjects for treatment of HIV-1 infection in real life practice
204731-An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of TRIUMEQ administered in Korean subjects for treatment of HIV-1 infection in real life practice
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

200304-Comparative efficacy and safety study of dolutegravir and lopinavir/ritonavir in second-line treatment
200304-Comparative efficacy and safety study of dolutegravir and lopinavir/ritonavir in second-line treatment
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

204862-Switch study to evaluate dolutegravir plus lamivudine in virologically suppressed human immunodeficiency virus type 1 positive adults (TANGO)
204862-Switch study to evaluate dolutegravir plus lamivudine in virologically suppressed human immunodeficiency virus type 1 positive adults (TANGO)
Immune, Inflammatory & Infections - Other
Active, not recruiting

No Limit

To find a center near you, please provide a Country or Postal Code.

201933-Drug Use Investigation for Tivicay® tablet (HRD Cooperative Investigation)
201933-Drug Use Investigation for Tivicay® tablet (HRD Cooperative Investigation)
Human Immunodeficiency Virus (HIV)
Recruiting
4-25

To find a center near you, please provide a Country or Postal Code.

205858-PH3b, DTG study in HIV-1 subjects completing IMPAACT Study P1093
205858-PH3b, DTG study in HIV-1 subjects completing IMPAACT Study P1093
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

201584-Study to evaluate the efficacy, safety, and tolerability of long-acting intramuscular cabotegravir and rilpivirine for maintenance of virologic suppression following switch from an integrase inhibitor in HIV-1 infected therapy naive participants
201584-Study to evaluate the efficacy, safety, and tolerability of long-acting intramuscular cabotegravir and rilpivirine for maintenance of virologic suppression following switch from an integrase inhibitor in HIV-1 infected therapy naive participants
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

201636-Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
201636-Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)